Abstract
Neurological symptoms are seen in patients with COVID-19 and can persist or re-emerge after clearance of SARS-CoV-2. Recent findings suggest that antibodies to SARS-CoV-2 can cross-react with mammalian proteins. Focusing on neurological symptoms, we discuss whether these cross-reactive antibodies could contribute to COVID-19 disease pathology and to the persistence of symptoms in patients who have cleared the initial viral infection.
MeSH terms
-
Antibodies, Monoclonal / biosynthesis
-
Antibodies, Neutralizing / biosynthesis
-
Antibodies, Viral / biosynthesis*
-
Autoimmunity
-
Betacoronavirus / immunology
-
Betacoronavirus / pathogenicity
-
Brain Diseases / complications
-
Brain Diseases / diagnosis
-
Brain Diseases / immunology*
-
COVID-19
-
Coronavirus Infections / complications
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / immunology*
-
Cross Reactions
-
Headache / complications
-
Headache / diagnosis
-
Headache / immunology
-
Humans
-
Pandemics
-
Parkinsonian Disorders / complications
-
Parkinsonian Disorders / diagnosis
-
Parkinsonian Disorders / immunology*
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / immunology*
-
SARS-CoV-2
-
Seizures / complications
-
Seizures / diagnosis
-
Seizures / immunology*
-
Tremor / complications
-
Tremor / diagnosis
-
Tremor / immunology*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Antibodies, Viral